GlobeNewswire·Nov 10, 2026, 4:16 PM ET

Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX; TSX:EPRX) entered into an ATM Sales Agreement with Jefferies LLC and Jefferies Securities, Inc. to establish an at-the-market equity program.
The ATM Program allows the Company to offer and sell up to US$125 million (or Canadian dollar equivalent) of common shares at prevailing market prices on the Toronto Stock Exchange, Nasdaq Global Select Market, or other existing trading markets.
Chief Financial Officer Alex Rothwell stated the program is a general corporate housekeeping item consistent with industry norms.
The Company has no current plan to utilize the ATM Program in the near term due to cash balances covering planned expenses until the second half of 2028.
The offering is conducted pursuant to prospectus supplements dated November 10, 2026, filed with Canadian securities commissions and the U.S. Securities and Exchange Commission.
The ATM Program will terminate upon the sale of all Offered Shares, termination of the agreement by the Agents or the Company, or the expiry of the Canadian Shelf Prospectus.
Documents related to the agreement are available on SEDAR+ in Canada and EDGAR in the United States.
Eupraxia is a clinical-stage biotechnology company focused on developing locally delivered, extended-release products using its proprietary Diffusphere™ technology.